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Abstract
Background:  CK5 positive cells represent progenitors for glandular and myoepithelial lineages of mammary epithelium.  During epithelial differentiation 
there is a gradual decrease of CK5 expression.  In case of benign lesions the proliferating luminal cells show a high expression of CK5.  Contrary, the 
majority of malignancies which are derived from differentiated glandular cells line do not reveal immunohistochemical staining with CK5 marker.  The aim 
of this study was to compare the expression of basal cytokeratin CK5 vs hormone receptors, HER2, Ki67 and molecular subtype’s immunohistochemically 
defined in the primary breast carcinomas of NST type.
Material and methods:  We processed 108 invasive breast carcinomas of NST type.  The specimens were formalin-fixed and paraffin-embedded as 
traditionally. Sections were immunostained (ER, PR, HER2, CK5 and Ki67) automatically with Leica Bond-Max autostainer.
Results:  Breast carcinoma of NST type was in majority of cases CK5 negative (94 cases/87%).  The positive CK5 cases had a high grade of differentiation. 
CK5 negative tumors were usually hormone positive, but in 8 cases/6.5% a combined simultaneous CK5-ER (PR) positive expression was determined. 
From 22 HER2 positive cases, 16 were CK5 negative. CK5 value correlated statistically significant with all used markers, except grade of differentiation: 
a positive Pearson coefficient was determined in relation to HER2 and Ki67, and a negative one compared to hormone receptors and molecular subtype.
Conclusions:  We support CK5 potential value in molecular subtype’s differentiation.  Breast carcinoma of NST type is usually CK5 negative and hormone 
positive.  The presence of cases with simultaneous expression of CK5 and hormone receptors is an open field to debate the existence of other, transient 
molecular subtypes and we expect a further confirmation in larger study groups.
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Introduction
The secretory portion of the normal breast consists of 
the following five distinct cell populations: committed stem 
(progenitor) cells which are CK5 positive, glandular precur-
sor cells which express all spectrum of cytokeratins (CK5+/ 
CK8/18/19+), glandular end cells, positive for luminal cytoke-
ratins (CK8/18/19+), myoepithelial precursor cells positive for 
CK 5/6+ and SMA+ (smooth muscle actin), and myoepithelial 
mature cells, SMA positive. The CK5 positive cells represent 
progenitors for both glandular and myoepithelial lineages of 
mammary epithelium. During epithelial differentiation there 
is a gradual decrease of CK5 expression. In case of benign 
lesions the proliferating luminal cells express in excess CK5 
protein and opposite, in case of the majority of malignancies 
glandular cells line do not reveal immunohistochemical stai-
ning with CK5 marker [1; 2].
Breast cancer is a heterogeneous disease with different 
clinical outcomes. It is one of the most common cancers in 
females worldwide. The modern classification purposes to 
divide it into at least five molecular subtypes which are: two 
hormone positive types (Luminal A and Luminal B) and 
three hormone negative types (HER-2 expressing, Basal-
like, and Normal breast-like), each with distinct clinical 
features, and different prognosis [3]. Nielsen et al. purposed 
to differentiate immunohistochemically these subtypes by 
a panel of four antibodies (ER, HER1, HER2, and cytoke-
ratin 5), point of view sustained also by Goldhirsch et al. 
(2013) that supplemented this panel with Ki67 as a marker 
of proliferation [4; 5].
The aim of this study was to compare the expression of 
basal cytokeratin CK5 vs hormone receptors, HER2, Ki67 and 
molecular subtypes immunohistochemically defined in the 
primary breast carcinomas of NST type.
Material and methods
Patients.  There were investigated primary breast carci-
nomas of 108 patients, 33-86 years old from the Oncological 
Institute, the Republic of Moldova during 2012-2013 years. 
No drug therapy preceded and all patients underwent radical 
mastectomy and lymph nodes dissection.  
Tissue processing and immunohistochemistry.  The 
specimens were fixed in 10% phosphate buffered formalin for 
24-48h and paraffin (Paraplast High Melt, Leica Biosystems) 
embedded as usual. For histopathological assessment 4-6 μm 
sections were cut and stained with hematoxylin and eosin. Two 
independent histologists reviewed the cases. Discrepancies 
in diagnoses were solved by consensus with simultaneous 
viewing. Histological grade was scored by the Scarff-Blo-
om-Richardson grading system. The immunohistochemical 
assessment included 5 markers: for ER (clone Er/6F11), PR 
(clone Pr16), and human epidermal growth factor receptor 2 
(HER2/polyclonal), marker of proliferation Ki67 (clone Ki67/
K2) and basal cytokeratin CK5 (clone CK5/ XM26) (tab. 1). 
Specimens were processed automatically on Leica Bond-Max 
autostainer (Leica Microsystems GmbH, Wetzlar, Germany). 
The hematoxylin solution, Harris modified (HHS32, Sigma-
Aldrich) was used for counterstaining. 
Microscopic evaluation.  Ki67 marker, as well as hormone 
receptors were counted using a semi-quantitative method 
performed by Suciu et al. (2014) [6].  For Ki67 marker we 
used a 14% threshold as a limit to distinguish positive/nega-
tive cases [5].
The anti-ER and anti-PR markers were scored as a 
percentage of nuclear positive stained cells at least to 1000 
cells.  We followed the guidelines of ER and PR assessment 
purposed by Allred, which are combining the percentage of 
positive cells with intensity of nuclear staining [7]. The cases 
scored as +1 – +3 were considered positive. The threshold of 
positivity was 10%. 
The HER2 status was interpreted in accordance with 
ASCO (American Society of Clinical Oncology) recommen-
dations [8]: HER2+0 – if no staining observed or weak, barely 
perceptible membrane staining until 10% of cells; HER2+1 – in 
case of a weak membrane staining of >10%; HER2+2 – in case 
of incomplete, weak/moderate circumferential membrane 
staining of more than 10% of tumor cells or complete circum-
ferential intense staining less than 10% of cells; HER2+3 – in 
case of intense, circumferential staining of more than 10% 
of tumor cells. Cases with HER2 scored as +2 and +3 were 
considered positive. The positive cells of normal ducts served 
as internal control. 
The CK5 expression was interpreted as Azoulay et al. pre-
viously defined: 0 – no tumor cells stained; +1 – less of 10% 
of tumor cells stained; +2 – 10-50% of positive tumor cells; 
+3 – more than 50% of tumor cells stained [9]. Expression was 
scored positive (>0) if any cytoplasmic and/or membranous 
staining tumor cells were observed. 
Table 1
The surrogate markers: source, dilution, systems of detection and retrieval, time of incubation
Antibody/Clone Source/incubation time /dilution Detection/time Retrieval system/time
ER/6F11 Leica Biosystem Newcastle Ltd, New-
castle Upon Tyne, UK/15 min/RTU
Bond Polymer Refine Detection 
System (Leica Biosystems, Newcastle 
Upon Tyne, UK), 15 min
Bond Epitope Retrieval Solution 1, 
(Leica Biosystems, Newcastle Upon 
Tyne, UK)/20 minPR/16
HER2 /polyclonal Dako Glostrup Denmark/30 min/RTU EnVision-HER/30 min Dako Target Retrieval Solution, pH6/20 min
Ki67/K2 Leica Biosystem Newcastle Ltd, New-
castle Upon Tyne, UK/15 min/RTU
Bond Polymer Refine Detection 
System (Leica Biosystems, Newcastle 
Upon Tyne, UK), 15 min
Bond Epitope Retrieval Solution2, 
(Leica Biosystems, Newcastle Upon 
Tyne, UK)/20 minCK5/ XM26
RTU: ready to use
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The results were grouped in 5 subgroups: 1. ER+ (and/
or PR+), HER2-, CK5-, Ki67<14 as Luminal A; 2. ER+ (and/
or PR+), HER2+, CK5- or ER+ (and/or PR+), HER2-, CK5-, 
Ki67>14 as Luminal B; 3. ER-, PR-, HER2+, CK5- as HER2 
over-expressed; 4. ER-, PR- and HER2-, CK5+ as Basal-like; 
5. ER-, PR-, HER2- and CK5- as 5NP (5 negative phenotype).
Image acquisition and data processing. Slides were exa-
mined on Nikon Eclipse 80i microscope with Nikon DS-Fi1 
installed camera by using Nis-elements 2.30 imaging software 
(Nikon Instruments Europe BV). A MS Access 2007 database 
was used to store and group the data.
Statistical analysis. The WINSTAT 2012.1 (R. Fitch 
Software, Bad Krozingen, Germany) software was used for a 
descriptive statistics, the mean value, standard error of mean 
and median were determined for Ki67. For all the tests a 
P ≤ 0.05 was considered significant. A Pearson's correlation 
(r) was used to determine the relationship between diffe-
rent variables for a P ≤ 0.05. The strength of the correlation 
was appreciated as: .00-.19 – “very weak”; .20-.39 –“weak”; 
.40-.59 – “moderate”; .60-.79 –“strong”; .80-1.0 as “very strong”.
Ethics. This study has been approved by the Ethics Com-
mittee of the “Nicolae Testemitanu” University of Medicine 
and Pharmacy from Chisinau, the Republic of Moldova (ap-
proval number 21/13/31.03.2014).
Results
The CK5 was evaluated as negative in 94 cases/87%. 
The ER marker was positive in 88 cases/81,5%, the PR in 
77 cases/71,3% and HER2 in 22 cases/20,4%. The Ki67 was 
encountered at high level (more than 14% of positive cells) 
in 58 cases/53,7% with a mean of 21,46±1,94 and median 15.
The G2 grade of differentiation was the most frequent 
registered (60 cases/55.6%), followed by G3 (40 cases/37%) 
and G1 (8 cases/7.4%). In relation to CK5 expression we 
realized that most of CK5 negative cases showed G2 and G3 
grade. We have to mention that majority of G1 cases (7 from 
8) were CK5 negative too (tab. 2).
By comparing the scores of markers expression we realized 
that majority of hormonal positive and HER2 negative cases 
had a lack of CK5 expression (tab. 3). Table 3
CK5 expression grade in relation to hormone receptors and HER2 scores
CK5 ER No % CK5 PR No % CK5 HER2 No %
0 0 13 12,0 0 0 24 22,2 0 0 74 68,5
0 1 4 3,7 0 1 8 7,4 0 1 4 3,7
0 2 11 10,2 0 2 14 13,0 0 2 6 5,6
0 3 66 61,1 0 3 48 44,4 0 3 10 9,3
1 0 3 2,8 1 0 3 2,8 1 0 5 4,6
1 1 1 0,9 1 1 1 0,9 1 3 2 1,9
1 3 3 2,8 1 2 1 0,9 2 0 2 1,9
2 0 2 1,9 1 3 2 1,9 2 3 2 1,9
2 3 2 1,9 2 0 2 1,9 3 0 1 0,9
3 0 2 1,9 2 2 2 1,9 3 2 2 1,9
3 1 1 0,9 3 0 2 1,9
3 3 1 0,9
Total 108 cases/100%
Table 4
CK5 expression grade vs molecular subtype
CK5
expression
Molecular
subtype No %
0 5NP 4 3,7
87%
0 Her2 6 5,6
0 Luminal A 36 33,3
0 Luminal B 48 44,4
1 Basal-like 1 0,9
13%
1 Her2 1 0,9
1 Luminal A 1 0,9
1 Luminal B 4 3,7
2 Her2 1 0,9
2 Luminal A 1 0,9
2 Luminal B 3 2,8
3 Basal-like 1 0,9
3 Her2 1 0,9
Total 108 100,0
Table 2
CK5 expression in relation to grade of differentiation
CK5 expression Grade  of differentiation No %
0 G1 7 6,5
87%0 G2 53 49,1
0 G3 34 31,5
1 G2 5 4,6
13%
1 G3 2 1,9
2 G1 1 0,9
2 G2 1 0,9
2 G3 2 1,9
3 G2 1 0,9
3 G3 2 1,9
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The most commonly determined molecular profile in our 
research was Luminal B (55 cases/50,9%), followed in regressi-
on by Luminal A (38 cases/35,2%), HER2+ (9 cases/8,3%), 5NP 
(4 cases/3,7%) and Basal-like (2 cases/1,9%). Three molecular 
subtypes, Luminal A, Luminal B and HER2 were determined 
in both groups, CK5 positive and CK5 negative, while 5NP 
was registered only in CK5 negative group and Basal-like in 
CK5 positive group only (tab. 4).
The CK5 expression correlated weakly, but statistically 
significantly with all markers, except grade of differentiation 
(tab. 5).
Discussion
Abd El Rehim et al. (2004) consider that the secretory por-
tion of the normal breast consists of the following five distinct 
cell populations: committed stem (progenitor) cells which 
are CK5 positive, glandular precursor cells which express all 
spectrum of cytokeratins (CK 5+/CK8/18/19+), glandular end 
cells, positive for luminal cytokeratins (CK8/18/19+), myoepi-
thelial precursor cells positive for CK5/6+ and SMA+ (smooth 
muscle actin), and myoepithelial mature cells, SMA positive 
[10]. By this, CK5 positive cells in fact represent progenitors 
for both glandular and myoepithelial lineages of mammary 
epithelium. During epithelial differentiation there is a gradual 
decrease of CK5 expression, associated with an increase in 
expression of CK8/18/19 in the glandular cells, and smooth 
muscle actin in the myoepithelial cells along the pathways 
of differentiation. By the Bocker W et al. (2002) data, in the 
lactating breast, there is a segregation of epithelial structures 
into CK8/18 expressing secretory zone and the proliferative 
zone which harbors cells of both glandular (CK8/18+) and 
basal /myoepithelial (CK 5/6+) type [11]. 
In case of benign lesions the proliferating luminal tumors 
show a high number of CK5/6 positive cells because of proli-
feration of both glandular and basal cells [12]. In Heatley M 
et al. (1995) opinion, the majority of malignancies which are 
derived from differentiated glandular cells line do not reveal 
immunohistochemical staining with CK5/6 leading, by this 
explaining both CK5 negativity in most lesions of atypical 
hyperplasia and ductal carcinoma in situ [13].
 Genes expression profiling has identified various breast 
carcinoma classes with prognostic significance [3; 14].The 
Table 5
Pearson’s correlation between surrogate markers, molecular subtype and grade of differentiation
CK5 ER PR HER2 Ki67 Subtype Grade
CK5
r   -0,35 -0,20 0,22 0,41 -0,27 0,07
p   0,0001 0,0212 0,0124 0,0000 0,0023 0,2332
Er
r -0,35   0,52 -0,39 -0,30 0,67 -0,08
p 0,0001   0,0000 0,0000 0,0009 0,0000 0,2056
Pr
r -0,20 0,52   -0,24 -0,17 0,47 -0,18
p 0,0212 0,0000   0,0071 0,0363 0,0000 0,0360
HER2
r 0,22 -0,39 -0,24   0,11 -0,54 0,00
p 0,0124 0,0000 0,0071   0,1195 0,0000 0,4836
Ki67
r 0,41 -0,30 -0,17 0,11   -0,38 0,25
p 0,0000 0,0009 0,0363 0,1195   0,0000 0,0047
Subtype
r -0,27 0,67 0,47 -0,54 -0,38   -0,15
p 0,0023 0,0000 0,0000 0,0000 0,0000   0,0618
Grade
r 0,07 -0,08 -0,18 0,00 0,25 -0,15  
p 0,2332 0,2056 0,0360 0,4836 0,0047 0,0618  
Note: Grade – grade of differentiation; Subtype – molecular subtype; r – Pearson correlation coefficient.  Statistical significant values are given in Bold.
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authors purposed initially to distinct 5 subtypes, as Luminal 
A, Luminal B, HER2+, Normal breast–like, and Basal-like. The 
luminal tumors were defined as hormone receptor–positive 
and negative for HER2 and usually tend to have a good pro-
gnosis. In con trast, HER2+ tumors are negative for hormone 
receptors and positive for HER2 and have been shown to have 
poor prog nosis. The existence of normal breast–like tumors 
is still debated, but majority of researches consider that it 
expresses genes characteristic of adipose tissue and other 
non-epithelial breast cells, with a relatively poor prognosis. 
Among all the molecular classes, Basal-like breast carcino-
ma seems to have the worst prognosis [15]. These tumors are 
negative for hormone receptors and HER2, and positive for 
CK5 and/or HER1 [16]. Basal-like tumors are also the most 
common type of tumors in patients with germline BRCA1 
mutations. Such tumors are considered as high proliferative 
ones, with a low cellular differentiation [17; 18]. Such results 
are in line with our data, in which from 14 CK5 positive cases 
only one was evaluated with G1. In accordance with Sood et 
al. (2014) the CK5 did not show statistically significant cor-
relation with age, tumor size and stage, histological type, the 
state of tumor margins, presence of lymphoid infiltrate and 
necrosis, lymph node status, and Ki67 positivity [18]. Authors 
reported a single significant correlation, CK5 vs tumors’ grade, 
result debated by Rao et al. (2013) and confirmed by us: CK5 
correlated significantly with all studied markers, except grade 
of differentiation [17] (tab. 5). 
Some authors debate in the literature whether triple-nega-
tive tumors (negative for hormone receptors and HER2, CK5 
positive) are synonym with Basal-like carcinoma [19]. Cheang 
et al. (2008) by using additional markers identified a cohort 
of patients with a significantly worse outcome in the group 
of triple-negative tumors, it means that breast carcinoma is 
not homogenous even inside the molecular subtypes [20]. 
This is in line with present research, where positive CK5 was 
determined in all molecular subtypes, defined by surrogate 
markers in accordance with Goldhirsch et al. (2013) criteria 
[5] (tab. 4). Moreover, in 9 of 14 cases CK5 positive marker 
was associated with Luminal phenotype. 
Conclusions
We support CK5 potential value in molecular subtype’s 
differentiation. Breast carcinoma of NST type is usually CK5 
negative and hormone positive. The presence of cases with 
simultaneous expression of CK5 and hormone receptors 
is an open field to debate the existence of other, transient 
molecular subtypes and we expect a further confirmation in 
larger study groups.
Conflict of Interests
The authors declare that there is no conflict of interests 
regarding the publication of this paper.
Acknowledgements
The authors are thankful to Professor Marius Raica and 
entire team from the Department of Microscopic Morpholo-
gy/Histology, Angiogenesis Research Center, “Victor Babes” 
University of Medicine and Pharmacy Timisoara, Romania, 
by whose enormous support this work could be done. This 
work was supported by Academy of Sciences of Moldova, 
institutional research project 15.817.04.09F, contract nr. 55 
Inst from 06.03.2015.
References
1. Laakso M, Loman N, Borg, et al. Positive breast cancer: true basal phe-
notype confined to BRCA1 tumors. Mod Pathol. 2005;18(10):1321-1328.
2. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 im-
munostaining using D5/16 B4 antibody in the spectrum of proliferative 
intraepithelial lesions of the breast. A comparative study with 34betaE12 
antibody. Virchows Arch. 2003;442(6):548-554.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast 
tumours. Nature. 2000;406:747-752.
4. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical 
characterization of the basal-like subtype of invasive breast carcinoma. 
Clinical Cancer Research. 2004;10(16):5367-5374.
5. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of 
women with early breast cancer: highlights of the St Gallen International 
Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. 
Ann Oncol. 2013;24(9):2206-23.
6. Suciu C, Muresan AM, Cornea R, et al. Semi-automated evaluation 
of Ki 67 index in invasive ductal carcinoma of the breast. Oncol Lett. 
2014;7:107-114.
7. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive fac-
tors in breast cancer by immunohistochemical analysis. Mod Pathol.
1998;11:155-168.
8. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for Human
Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American 
Society of Clinical Oncology/College of American Pathologists Clinical 
Practice Guideline Update. J Clin Oncol. 2013;31(31):3997-4013.
9. Azoulay S, Lay M, Fruneaux P, et al. KIT is highly expressed in adenoid 
cystic carcinoma of the breast, a basal-like carcinoma associated with a 
favorable outcome. Mod Pathol. 2005;18:1623-31.
10. Abd El Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and 
basal cytokeratins in human breast carcinoma.  J Pathol. 2004;203:661-71.
11. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the 
human breast give rise to glandular and myoepithelial cell lineages: A 
new cell biological concept. Lab Investig. 2002;82:737-45.
12. Otterbach F, Bunkfalvi A, Bergner S, et al. Cytokeratin 5/6 immunohis-
tochemistry assists the differential diagnosis of atypical proliferations of 
the breast. Histopathology. 2000;37:232-40.
13. Heatley M, Maxwell P, Whiteside C, et al. Cytokeratin intermediate fila-
ment expression in benign and malignant breast disease. J Clin Pathol.
1995;48:26-32.
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast
carcinomas distinguish tumor subclasses with clinical implications. Proc
Natl Acad Sci USA. 2001;98:10869-10874.
15. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast 
tumor subtypes in independent gene expression data sets. Proc Natl Acad 
Sci USA. 2003;100:8418-8423.
16. Collins LC, Martyniak A, Kandel MJ, et al. Basal cytokeratin and epi-
dermal growth factor receptor expression are not predictive of BRCA-1 
mutation status in women with triple-negative breast cancers. Am J Surg 
Pathol. 2009;33:1093-1097.
17. Rao C, Shetty J, Kishan Prasad HL. Immunohistochemical profile and 
morphology in triple-negative breast cancers. Journal of Clinical and 
Diagnostic Research. 2013;7(7):1361-1365.
18. Sood N, Nigam JS. Correlation of CK5 and EGFR with Clinico-
pathological Profile of Triple-Negative Breast Cancer. Patholog Res Int. 
2014;14:1864.
19. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast 
cancer synonymous [letter]? Clin Cancer Res. 2008;14:618.
20. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined 
by five biomarkers has superior prognostic value than triple-negative 
phenotype. Clin Cancer Res. 2008;14:1368-1376.
